A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: Focus on somnolence

Journal of Clinical Psychiatry

Volumn 69, Issue 2, 2008, Pages 302-309

  Gao, Keming ^a,c   Ganocy, Stephen J ^a   Gajwani, Prashant ^a   Muzina, David J ^b   Kemp, David E ^a   Calabrese, Joseph R ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ALLERGIC REACTION; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HALLUCINATION; HUMAN; INSOMNIA; LANGUAGE; MANIA; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PUBLICATION; RASH; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; XEROSTOMIA;

EID: 41549116886     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0217     Document Type: Article

References (53)

1. Murray RM, Sham P, Van Os J, et al. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 2004;71:405-416
2. Muir WJ, Thomson ML, McKeon P, et al. Markers close to the dopamine D5 receptor gene (DRD5) show significant association with schizophrenia but not bipolar disorder. Am J Med Genet 2001;105:152-158
3. McDonald C, Bullmore ET, Sham PC, et al. Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry 2004;61:974-984
4. Detera-Wadleigh SD, Badner JA, Berrettini WH, et al. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci U S A 1999;96:5604-5609
5. Park N, Juo SH, Cheng R, et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol Psychiatry 2004;9:1091-1099
6. Gao K, Gajwani P, Elhaj O, et al. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005;66:1376-1385
7. Gao K, Gajwani P, Muzina D, et al. The effects of antipsychotics on mood. Adv Schizophr Clin Psychiatry 2006;2:120-127
8. Ketter TA, Nasrallah HA, Fagiolini A. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacol Bull 2006;39:120-146
9. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-886
10. Bech P, Baastrup PC, de Bleeker E, et al. Dimensionality, responsiveness and standardization of the Bech-Rafaelsen Mania Scale in the ultra-short therapy with antipsychotics in patients with severe manic episodes. Acta Psychiatr Scand 2001;104:25-30
11. Samellas D, Read P, Cookson JC. Antipsychotic drugs in mania: factors predicting use of antipsychotic medication following inpatient treatment of mania. Int Clin Psychopharmacol 2004;19:291-297
12. Tohen M, Vieta E, Calabrese JR, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch Gen Psychiatry 2003;60:1079-1088
13. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360
14. Thase ME, Macfadden W, Weisler EH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BPLDER II Study). J Clin Psychopharmacol 2006;26:600-609
15. Jaeschke R, Guyatt G, Shannon H, et al. Basic statistics for clinicians: 3. Assessing the effects of treatment: measures of association. CMAJ 1995;152:351-357
16. McQuay HJ, Moore AR. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-720
17. Guyatt G, Cook D, Devereaux PJ, et al. Therapy. In: Guyatt G, Rennie D, eds. Users Guides: Essentials of Evidence-Based Clinical Practice. Chicago, Ill: American Medical Association; 2002:55-79
18. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-1312
19. Altman DG. Why we need confidence intervals. World J Surg 2005;29:554-556
20. Montori VM, Kleinbart J, Newman TB, et al. Tips for learners of evidence-based medicine, 2: measure of precision (confidence intervals). CMAJ 2004;171:611-615
21. Belia S, Fidler F, Williams J, et al. Researcher misunderstood confidence intervals and standard error bars. Psychol Methods 2005;10:389-396
22. Cumming G, Finch S. Inference by eye: confidence intervals and how to read pictures of data. Am Psychol 2005;60:170-180
23. Payton ME, Greenstone MH, Schenker N. Overlapping confidence intervals or standard error intervals: what do they mean in terms of statistical significance? J Insect Sci 2003;3:34
24. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658
25. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20:536-546
26. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
27. Tohen M, Jacobs TG, Grundy SL, el al. Efficacy of olanzapine in acute bipolar mania: a double blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-849
28. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomized, placebo-controlled studies. Curr Med Res Opin 2005;21:923-934
29. Hirschfeld RMA, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-1065
30. Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005;15:75-84
31. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania. Br J Psychiatry 2005;187:229-334
32. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748
33. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301-310
34. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizo-affective disorder. J Clin Psychiatry 2002;63:763-771
35. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
36. Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
37. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
38. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
39. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
40. Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-184
41. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491-505
42. Tohen M, Bowden C, Calabrese J, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-256
43. Keck PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-637
44. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
45. Beasley CM, Sutton VK, Hamilton SH, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23:582-594
46. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomized, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573-585
47. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-1226
48. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole vs haloperidol in acute bipolar disorder. Br J Psychiatry 2005;187:235-242
49. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262
50. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-1404
51. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
52. Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156:79-87
53. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223